Sen. Elizabeth Warren is not done with Scott Gottlieb.

Already peeved that the former Food and Drug Administration Commissioner joined the Pfizer (PFE) board just weeks after leaving the agency, the Massachusetts Democrat and presidential candidate expressed “disappointment” that Gottlieb refused to resign as she requested earlier this month.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I find it amazing that as Elizabeth Warren and many others rightly condemn Pfizer and the FDA of corruption doing poor drug trials and hiding side effects etc. But when it comes to vaccines suddenly pharma and the FDA are saints and can do no wrong. She wants forced injection for all kids and all vaccines, no freedom, no choice.

  • May I observe, possibly again?, that the objection to Scott Gottlieb was that he was coming back from industry when he took the post? It appears he was as good as could have been found at the time by the current administration.
    In addition, the big press was to save money on biologics and he pushed for biosimilars, as everyone except the patent holders wanted. Now the rumblings that Pfizer is big into biosimilars – among other things, buying Hospira helped that.

    • The objection is to an FDA official at the highest level working concurrently as a top business advisor for Pfizer. Gottlieb has an enormous amount of influence in government as well as an insane amount of information that could potentially give Pfizer a huge unfair advantage. The objection is spelled out in the article. Further, it is EXACTLY the kind of swamp conditions that Trump promised during his campaign to end.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy